[Previous Months][Date Index][Thread Index][Join - Register][Login]
[Message Prev][Message Next][Thread Prev][Thread Next]


Diabetes In Control Newsletter - http://www.diabetesincontrol.com

The Newsletter for Professionals in Diabetes Care

 December 26, 2000,  Issue 32

Item #4
Diabetics, This Bud is Good For You??

Antioxidants in beer might help with complications of with eyes and heart

  A beer a day may help stave off some of the ravages of aging.

Although it may sound too good to be true, the results of early lab
experiments seem to point in that direction.

Pennsylvania researchers are looking at whether the antioxidants in beer
have a beneficial effect on blood vessels, thus reducing the risk of heart
disease. And researchers in Canada are exploring whether the antioxidants
also can prevent cataracts, especially in diabetics who are prone to
developing them.

The lenses of rats and cows are damaged when exposed to high glucose
levels, but appear to be protected by the type of antioxidants found in
beer, the Canadian researchers say. Antioxidants, which occur in higher
concentrations in dark beers, destroy a type of oxygen molecule that
damages cell membranes.  For complete study:

Item  #9
New Product by Ortec shows 100% wound closure

Ortec International Inc. reported a pilot diabetic ulcer trial preliminary
analysis, in this case conducted with computer scans, showed that, at 12
weeks, 5 of 9 patients treated with CCS saw complete wound closure. This
is compared with 2 of 7 patients for the control group treated with
standard care. This is part of an eight-center study involving 32

Ortec's CCS Shows 56 Percent of Diabetic Ulcer Patients Achieved 100
Percent Closure Versus 29 Percent in Standard of Care Group In Preliminary
12-Week Analysis.  For more info:

Item #10
Risk of Nephropathy Can Be Detected Before the Onset of Microalbuminuria
in Early Years After Diagnosis of Type 1 Diabetes

The object was the early detection of a rise in albumin excretion within
the normal range could permit early intervention to prevent the
development of microalbuminuria (MA) in genetically susceptible subjects
with type 1 diabetes. In the Oxford Regional Prospective Study,  urine
albumin excretion during the first years after diagnosis of childhood type
1 diabetes was examined

511 subjects aged <16 years were recruited at diagnosis and followed for a
median of 6 years. In 78 subjects, an annual assessment of the
albumin-to-creatinine ratio (ACR) in three morning first-void urine
samples detected MA (males: ACR >3.5 mg/mmol, females: ACR >4.0 mg/mmol in
two of three urine samples). In 63 of these subjects and 396
normoalbuminuric diabetic control subjects, rates of change of the ACR
were calculated as the slope of the ACR over diabetes duration. For the
results: www.diabetesincontrol.com/issue32/item10.htm

Item #11
Cream May Help To Control Neuropathy Suffering

A novel treatment that could substantially reduce the number of
amputations suffered by insulin-dependent diabetics has taken a major step
forward in its development.

The treatment is expected to substantially reduce the number of
amputations suffered by insulin-dependent diabetics.  Biopharmaceutical
company GroPep and the International Diabetes Institute in Melbourne have
recruited 50 patients to test the product over the next seven months.  For
more info: www.diabetesincontrol.com/issue32/item11.htm

Item #12
Low-Dose Ramipril Reduces Microalbuminuria in Type 1 Diabetic Patients
WITHOUT Hypertension

Results of a randomized controlled trial

The object was to assess if 1.25 mg and/or standard 5 mg doses of the ACE
inhibitor ramipril (Altace .)could prevent progression of microalbuminuria
(incipient diabetic nephropathy) in normotensive type 1 diabetic patients.

This study used a multicenter randomized placebo-controlled double-blind
parallel group, and was conducted over 2 years in 28 outpatient diabetic
clinics in the U.K. and Ireland. The screening consisted of 334 type 1
diabetic patients with suspected microalbuminuria and normal blood
pressure; of these, 140 patients 18-65 years of age with a diagnosis of
type 1 diabetes and persistent microalbuminuria, defined as urinary
albumin excretion rate (AER) of 20-200 5g/min, were enrolled in the study.
For Results: www.diabetesincontrol.com/issue32/item12.htm

Item #13
Update on Diabetes Education

One recent large survey of 1,489 patients with diabetes revealed that 22%
received exercise counseling, 82% received a blood pressure measurement,
and only 5% received advice to take aspirin daily.2 On the other hand,
two-thirds of patients received some type of lipid-lowering medication.2
These results suggest that American physicians are paying more attention
to dyslipidemia but are ignoring other aspects of the treatment
(especially primary prevention) of macro-vascular disease. Interestingly,
the least controversial and least expensive aspects of this care (blood
pressure measurement, exercise counseling, aspirin prescription) are the
ones for which we have the greatest room for improvement.

2Meigs JB, Stafford RS: Cardiovascular disease prevention practices by
U.S. physicians for patients with diabetes. J Gen Intern Med 15:220-28,

Item #14**
Non-invasive Detection of Hypoglycemia Using A Novel, Fully Biocompatible
and Patient Friendly Alarm System

Hypoglycemia is a common complication of diabetes treatment with either
insulin or sulfonylureas and is particularly common with intensified
insulin regimens.  Episodes are often distressing and carry the risk of
serious neurological and cardiovascular sequelae. Hypoglycemia is
especially hazardous in patients with longstanding type 1 diabetes who
have lost the early warning symptoms of falling blood glucose levels.
Nocturnal episodes are also potentially dangerous and have been implicated
when diabetic patients have been found unexpectedly dead in bed.
Hypoglycemia is one of the complications of diabetes most feared by
patients, on a par with blindness and renal failure.

Intensive research has been devoted to the development of hypoglycemia
alarms, exploiting principles that range from detecting changes in the
electroencephalogram or skin conductance (due to sweating) to measurements
of subcutaneous tissue glucose concentrations by glucose sensors. As yet,
however, none has proved sufficiently reliable or unobtrusive to be useful
in clinical practice.

The following is a novel alarm system that can detect hypoglycemia before
the patient notices any symptoms and that operates robustly in a uniquely,
patient friendly fashion. The reports were volunteered spontaneously and
independently by the patients.

For the whole story: www.diabetesincontrol.com/issue32/item14.htm

____________NetZero Free Internet Access and Email_________
Download Now     http://www.netzero.net/download/index.html
Request a CDROM  1-800-333-3633
for HELP or to subscribe/unsubscribe, contact: HELP@insulin-pumpers.org
send a DONATION http://www.Insulin-Pumpers.org/donate.shtml